Vol. 41 | No. 2 | July-December 2013 Back

Open Access

A Meta-analysis on the Effects of Tolvaptan in Patients with Chronic Heart Failure

Philipp C. Ines, Francis Charles L. Fernandez, Francis Carl L. Catalan, Irene L. Celedonio, Florido A. Atibagos Jr
Dec 2013 DOI 10.69944/pjc.6fac71c909

Abstract

BACKGROUND: Vasopressin levels are often elevated in heart failure patients and left ventricular dysfunction, and this may contribute to the increase in systemic vascular resistance via stimulation of the V1a receptor. Among the recent novel therapies for heart failure are the vasopressin receptor antagonists. Tolvaptan is an oral, non-peptide, selective vasopressin V2-receptor antagonist that causes aquaresis by acting on the distal nephron to increase secretion of electrolyte-free water. This meta-analysis aimed to test the hypothesis that tolvaptan is beneficial and results in clinical improvement in the treatment of heart failure. 

METHODS: This was a meta-analysis that included randomized controlled trials that compared the efficacy of tolvaptan 30 mg daily vs placebo among heart failure patients. We obtained relevant publications from PubMed, Cochrane and Australasian Medical Index. Abstracted data were assessed from the five (5) included studies using the JADAD Quality Scale. Outcomes measured were changes in body weight and serum sodium levels, from baseline to 24 hours of initiating treatment and at the end of follow-up. Data analysis was done using the Review Manager 5 software version 5.1.7. Analysis of the mean difference was used as effect measure. 

RESULTS: In this meta-analysis, the total pooled patient population was 4,899 patients (2,281 patients assigned to the tolvaptan group and 2,279 patients assigned to the placebo group). The outcome of the mean difference in body weight after 24 hours and at end of follow-up was -0.93 kg (95% CI: -1.12 to -0.74) and -1.34 kg (95% CI: -1.66 to -1.02) respectively. The outcome of the mean difference in serum sodium after 24 hours of treatment and at end of follow-up was 3.05 mEq/L (95% CI: 1.85 to 4.25) and 2.25 mEq/L (95% CI: 0.83 to 3.66) respectively. 

CONCLUSION: This meta-analysis demonstrated significant weight reduction and increase in serum sodium in patients with heart failure treated with tolvaptan during the first day and up to the end of follow-up treatment. These are important properties for the treatment of heart failure. 

KEYWORDS: Tolvaptan, Heart Failure, Meta-Analysis.

References
  1. Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M., Francis, G.S., Ganiats, T.G., Jessup, M., Konstam, M.A., Mancini, D.M., Michl, K., Oates, J.A., Rahko, P.S., Silver, M.A., Stevenson, L.W., Yancy, C.W., Antman, E.M., Smith, S.C., Adams, C.D., Anderson, J.L., Faxon, D.P., Fuster, V., Halperin, J.L., Hiratzka, L.F., Hunt, S., Jacobs, A.K., Nishimura, N., Ornato, J.P., Page, R.L., and Riegel, B. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult : A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154-e235. 
  2. Goldsmith SR. Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure. Congest Heart Fail 2002;8:251-6. 
  3. Schrier, R.W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J.G., Czerwiec, F.S., Orlandi, C. for the SALT Investigators. Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia. N Engl J Med 2006;355:2099-112. 
  4. De Luca L, Klein L, Udelson JE, et al. Hyponatremia in patients with heart failure. Am J Cardiol 2005;96:19L-23L. 
  5. Gheorghiade, M., Konstam, M.A., Burnett, J.C., Grinfeld, L., Maggioni, A.P., Swedberg, K., Udelson, J.E., Zannad, F., Cook, T., Ouyang, J., Zimmer, C., Orlandi, C. For the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007 Mar 28;297(12):1332-43. 
  6. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12. 
  7. Gheorghiade, M., Niazi, I., Ouyang, J., Czerwiec, F., Kambayashi, J., Zampino, M., Orlandi, C. Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial. Circulation. 2003;107:2690-2696. 
  8. Konstam, M.A., Gheorghiade, M., Burnett, J.C., et al. Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial. JAMA. 2007;297(12):1319-1331. 
  9. Udelson, J.E., Bilsker, M., Hauptman, P.J., Sequeira, R., Thomas, I., O’Brien, T., Zimmer, C., Orlandi, C., Konstam, M.A. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail. 2011 Dec;17(12):973-81. 
  10. Gheorghiade, M., Gattis, W.A., O’Connor, C.M., Adams, K.F., Elkayam, U., Barbagelata, A., Ghali, J.K., Benza, R.L., McGrew, F.A., Klapholz, M., Ouyang, J., Orlandi, C. Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004 Apr 28;291(16):1963-71. 
  11. Matsuzaki, M., Hori, M., Izumi, T., Fukunami, M. For the Tolvaptan Investigators. Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study). Cardiovasc Drugs Ther (2011) 25 (Suppl 1):S33–S45. 
  12. Elkayam, U., Bitar, F., Akhter, M.W., Khan, S., Patrus, S., Derakhshani, M. Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations. J Cardiovasc Pharmacol Ther. 2004;9:227-241. 
  13. Udelson, J.E., Orlandi, C., Ouyang, J., Krasa, H., Zimmer, C.A., Frivold, G., Haught, W.H., Meymandi, S., Macarie, C., Raef, D., Wedge, P., Konstam, M.A., Gheorghiade, M. Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction. J Am Coll Cardiol 2008;52:1540–5.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.